Unlike MET gene amplifications and protein overexpressions, MET exon 14 skipping mutations are only found as a primary oncogenic driver in around 3–4% of NSCLC patients, particularly in older patients with sarcomatoid histology [51], and are not reported as resistance mechanisms of EGFR TKIs. Here, EGFR is linked to non-small cell lung carcinoma.